Rossari Biotech Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/fgqqstw3qivi43t52oyccxc4.pdf

Key Takeaways


HPPC: The Growth Engine

Menezes: "The run-of-the-mill products Ethoxylates most Ethoxylaters make, but all these different kinds of additions are what we are doing. One of the latest ones is, as I said, Silicone surfactant which very few people do, because the reaction is quite a tough reaction, and it contains Hydrosilylation also, which is also a very controlled kind of reaction."

Capacity Constraints & The Dahej Build

Menezes: "Practically, we are using 100% capacity in ethoxylation."

Textile Specialties: The Drag

Chari: "In Textile chemicals, we don't see any big imports coming into India. The demand is not so strong. What had happened is in COVID, there was a big demand because American consumers were given extra money by the government and the focus was on hygiene and hence there was lot of disposables taking place every month and they were buying a lot of towels and bed sheets and linens. Now, that has slackened off."

Exports & Customer Concentration

Chari: "Exports now are nearly 23%, which is the highest ever in our history."

Margins & Profitability


Product Pipeline & New Initiatives


Guidance & Commitments

CommitmentSpecificsTimeline
FY24 revenue growth10-12% growth maintainedFY24
FY25 revenue growthMid-teen (15%) top-line growthFY25
Dahej expansion commissioningPhased completion of both projectsQ3 FY25
First Ethoxylation capacity ramp-upNew capacity onlineWithin 5 months
Tristar distillation capacityAddition complete4-5 months
CAPEX revenue contributionMost revenues begin; full ramp-up in FY26Late FY25 / FY26
Q4 FY24 EBITDA marginSimilar to Q3; sustainable range 13.67-14.12%Q4 FY24
Gross marginMaintain 30%Next quarter
PEG Powders product readinessProduct ready6 months
Lubricants product line launchLaunched in India3-4 months
CAPEX funding mix75:25 debt-to-internal-accrualsOngoing
Asset turn on new CAPEXAverage around 4-5xFY25/FY26

Key Metrics

MetricQ3 FY24
Consolidated revenue₹463.8 cr, +19% YoY
EBITDA₹63.7 cr, +18% YoY
EBITDA margin13.7%
PAT₹34.4 cr, +34% YoY
Gross margin30%, expected to be maintained
HPPC division revenue growth+31% YoY, volume-driven
Textile Specialty division revenue growth-13% YoY, though volumes intact
Animal Health division revenue growth+22% QoQ
Revenue mixHPPC 77%, Textile Specialty 18%, Animal Health 5%
Overall volume growth30%-35%+ YoY
Exports share23% of revenue, highest ever
Ethoxylation capacity utilization85%+, fully utilized across facilities
Overall capacity utilization~55%, near peak formulation levels
FY25 revenue growth guidance~15% (mid-teen)
FY25 EBITDA margin guidance13.67%-14.12%
Dahej expansion total CAPEX₹180 cr, commissioning phased through Q3 FY25